Genentech and Biogen Idec Announce Positive Results From a Phase 2 ...
DG News - USA
... announced today that a phase 2 study of Rituxan(R) (Rituximab) for relapsing-remitting multiple sclerosis (RRMS) met its primary endpoint. ...

Positive Results From Phase II Trial Of Rituxan In Relapsing ...
Medical News Today (press release) - UK
... (Nasdaq: BIIB) announced today that a Phase II study of Rituxan® (Rituximab) for relapsing-remitting multiple sclerosis (RRMS) met its primary endpoint. ...